November 10, 2009

NVAX Special Opinion

If any new investors to NVAX are panicking because of this article on Motley Fool, fear not. The Fool used to be a good source, but with their open source approach of letting anyone write articles, it has become a general bulletin board where everyone is free to dish their opinion. For instance, the author Tim Hanson has completely missed Novavax's long standing work in virus like particle (VLP) technology based vaccines for seasonal flu.
In fact NVAX is currently initiating phase II studies on comparing the dosing of its VLP based vaccine to existing flu vaccines (of other companies) {press release pdf}.

The problem with this approach is that there is no objective or comprehensive coverage of companies. Instead, we have a piecemeal approach picking on factors and comments on "absence of long term plans" -(paraphrased).
Tim Hanson says:
"I'm not here to be negative about either Novavax"
That was a funny circuitious route towards attacking a company which has very clear long term plans. Especially with long term manufacturing agreements with Cadila (india) and another company in Spain. They also have seasonal flu vaccines for long term (let me see) EVERY YEAR. Stop whining about sour grapes and actually make some real research. In addition, NVAX CEO has come to Novavax with 25 yrs big pharma experience because he saw big potential here.

Anyways, i am sitting in NVAX, long term with several long calls for next year. I am not concerned much. But what I am concerned is for small retail investors (who I was one of 3 years back) who would be misled by these opinions posing as research.
With today's search capabilities, it is quite easy to come up with a timeline of almost anything. In case of NVAX, you can check out their timeline with vaccine development and other progress here.

No comments:

Post a Comment

Your comments and opinions here!

Join the Discussion